New Haven, Conn, April 19, 2017 (GLOBE NEWSWIRE) — Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that there will be nine presentations on Melinta programs at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April 22-25, 2017 in Vienna, …
The post Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017 appeared first on ForexTV.
April 19, 2017 at 11:54PM
from Nasdaq NewsFeed
No comments:
Post a Comment